Indication

Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.
Sensipar® should not be used in adult patients with CKD who are not on dialysis because of an increased risk of low calcium levels.
+

Do you have concerns about your ability to pay for Sensipar®?

Amgen Assist® offers comprehensive coverage assistance

Enrollment in Sensipar®
Pharmacy Card Program
Commercial Insurance Patients 

Can reduce Sensipar®* co-pay to
as low as $5 for eligible patients

Referral to Amgen
Safety Net Foundation
Uninsured/Underinsured Patients

Amgen Safety Net Foundation may be able to provide Sensipar® at no cost to eligible patients

Referral to Independent Co-pay Foundations
Medicare Patients
Commercial Insurance Patients
* For patients with commercial prescription insurance. Program details and eligibility criteria listed below.

Provided through independent charitable patient assistance programs; program eligibility is based on the charity’s criteria. Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.
Contact Amgen Assist® by phone Monday through Friday, 8:00 am to 8:00 pm ET for coverage and reimbursement support information.
1-800-272-9376

Click on your insurance type below to find out more:

The examples of common insurance types below can help you better understand potential coverage for Sensipar®.
Standard Medicare Part D/Non-LIS
Patients on Medicare Part D may be subject to Medicare’s coverage gap, also called the "Donut Hole."13,14
Standard Medicare Part D includes those who have purchased a Part D prescription plan but who have sufficient assets or income that disqualify them from receiving Medicaid or the LIS.
Medicare Part D with LIS§
You are not subject to Medicare’s coverage gap, also called the "Donut Hole." Contact Amgen Assist® to determine your eligibility. Medicare Part D beneficiaries with full LIS status include dual eligibles (Medicare/Medicaid) and those with income at or below 135% of the FPL. Beneficiaries with income between 135% and 150% of FPL can qualify for partial LIS; these patients pay 15% of drug cost until the total drug spend reaches $7,062 and then only up to $7.40 per prescription.14

§ The dual-eligible section includes Medicare/Medicaid, other Medicare patients who qualify for the Part D LIS, and government assistance. These patients have reduced cost-sharing and are not subject to the coverage gap.
Commercial Insurance

The approval rate for Sensipar® (cinacalcet) commercial claims is 93%.15

The Sensipar® Pharmacy Card**: For Commercial insurance patients including Medicare patients with commercial pharmacy benefit and healthcare exchange patients with commercial insurance

The Sensipar® Pharmacy Card can lower your Sensipar® co-pay to as low as $5.00, if you qualify
  • For all commercial patients, including Medicare patients with commercial pharmacy benefit, healthcare exchange patients, COBRA, etc
  • No income eligibility requirements
  • The Sensipar® Pharmacy card pays up to $6,000 per year, including co-payments, co-insurance, and prescription deductible
  • Patients must re-enroll every 12 months in order to continue using the Sensipar® Pharmacy Card

Steps for using the Sensipar® Pharmacy Card:

1
Activate the Sensipar® Pharmacy Card at www.sensiparpharmacycard.com or call Amgen Assist® at 800-272-9376 Monday through Friday, 8:00 am to 8:00 pm ET
2
Present the Sensipar® Pharmacy Card at the pharmacy when filling the Sensipar® prescription

For rare cases when a mail-order pharmacy does not accept the Sensipar® Pharmacy Card, please visit www.sensiparpharmacycard.com or call Amgen Assist® at 800-272-9376 for instructions on obtaining and submitting a reimbursement form.

** Open to patients with a Sensipar® prescription and commercial insurance for Sensipar®. Patients may not seek reimbursement for value received from the Sensipar® Pharmacy Card program from any third-party payers, including a flexible spending account or healthcare savings account. This program is not open to uninsured patients or patients receiving prescription reimbursement under any federal, state or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law. If at any time patients begin receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patients will no longer be able to use this card and you must call Amgen Assist® at 800-272-9376 (8:00 am-8:00 pm ET, Monday-Friday) to stop participation. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance. This is not health insurance.

COBRA = Consolidated Omnibus Budget Reconciliation Act; HPT = hyperparathyroidism; LIS = low-income subsidy.
Uninsured or Limited Drug Coverage
Amgen Safety Net Foundation may be able to provide Sensipar® at no cost to eligible patients

For more details visit:
www.amgensafetynetfoundation.com

Important Safety Information

  • Sensipar® (cinacalcet) treatment should not be started if you have low calcium levels. Ask your doctor about the normal ranges. Life threatening events and fatal outcomes associated with low calcium levels have been reported in patients treated with Sensipar®, including in children.
  • Low calcium levels may potentially result in abnormal heart rhythms, known as ventricular arrhythmia, and have been reported in patients taking Sensipar®. 
  • Before starting Sensipar®, tell your doctor if you are taking medication to prevent seizures or have had seizures in the past. Report any seizure episodes while on Sensipar® therapy.
  • Very infrequent cases of low blood pressure, worsening heart failure, and/or abnormal heart rhythm (arrhythmia) have been reported in patients with impaired heart function taking Sensipar®.
  • Gastrointestinal (GI) bleeding, mostly upper GI bleeding, has happened in patients using Sensipar®. The exact cause of GI bleeding is unknown. Tell your healthcare provider if you have stomach pain, bloody or black stool, or if you vomit bloody or black material. Also tell your healthcare provider if you have nausea or vomiting that is getting worse.
  • While on Sensipar®, your doctor should perform repeated blood tests to monitor calcium, phosphorus, and intact parathyroid hormone (iPTH) levels. Very low and very high levels of PTH should be avoided to help maintain bone health. Very low levels (iPTH < 100 pg/mL) of PTH may cause a condition your doctor may refer to as adynamic bone disease.
  • Patients with moderate to severe liver impairment should be monitored throughout treatment with Sensipar®.
  • Tell your doctor if you experience any muscle spasms, aches or cramping, tingling in your limbs, or seizures.
  • In clinical trials, the most common side effects reported in patients were nausea, vomiting, and diarrhea.
If you have any questions about this information, be sure to discuss them with your doctor.


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088 (332-1088).

Indication

Sensipar® (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis.
Sensipar® should not be used in adult patients with CKD who are not on dialysis because of an increased risk of low calcium levels.
References: 1. Sensipar® (cinacalcet) prescribing information, Amgen. 2. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288:F253-F264. 3. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care. 2008;35:215-237, v-vi. 4. Uhlig K, Berns JS, Kestenbaum B, etal. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2010;55:773-799. 5. Ureña-Torres P, Bridges I, Christiano C, et al. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant. 2013;28:1241-1254. 6. Bringhurst FR, Demay MB, Kronenberg HM. Hormones and disorders of mineral metabolism: basic biology of mineral metabolism. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier; 2008:1203-1223. 7. Pollak MR, Yu ASL,Taylor EN. Disorders of calcium, magnesium, and phosphate balance: disorders of phosphate homeostasis. In: Brenner BM, Levine SA, eds. Brenner & Rector's The Kidney. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:602-604. 8. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148-157. 9. Lorenzo JA, Canalis E, Raisz LG. Metabolic bone disease. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders Elsevier; 2008:1269-1310. 10. Goodman WG, Quarles LD. Vitamin D,calcimimetics,and phosphate-binders. In: Brenner BM, Levine SA, eds. Brenner & Rector's The Kidney. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:1904-1927. 11. Мое SM, Drüeke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol. 2003;23:369-379. 12. Data on file, Amgen; [Clinical Study Report 20070360-Incident Dialysis Study; June 27, 2012]. 13. Kaiser Family Foundation. The Medicare Prescription Drug Benefit Fact Sheet: October 2010. http://www.kff.org/medicare/upload/7044-11.pdf. Accessed July 2, 2012. 14. Centers for Medicare & Medicaid Services. Announcement of Calendar Year (CY) 2016 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter. April 2015. Available at: https://www.cms.gov/Medicare/ Health-Plans/MedicareAdvtgSpecRateStats/Downloads/Announcement2016.pdf. Accessed November 9, 2015. 15. Data on file, Amgen; [IMS FIA Health Claims Data for All Patients; July 2015].